Approved for use through 07/31/2012. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)	
Applicant/Patent Owner: Richard F. Labaudiniere et al.	
Application No./Patent No.: 10/568252 Filed/Issue Date: 08/02/2006	
Entitled: Antibiotic Cycloalkyltetrahydroquinoline Derivatives	
Biota Scientific Management Pty Ltd , a corporation (Name of Assignee) , a Corporation (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)	
states that it is:	
1. the assignee of the entire right, title, and interest in;	
2. an assignee of less than the entire right, title and interest in (The extent (by percentage) of its ownership interest is%); or	
3. the assignee of an undivided interest in the entirety of (a complete assignment from one of the joint inventors was made)	
in the patent application/patent identified above by virtue of either:	
A. An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached.	
B. A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:	
1. From: Richard F. Labaudiniere To: Oscient Pharmaceuticals Corporation	
The document was recorded in the United States Patent and Trademark Office at	
Reel <u>018145</u> , Frame <u>0491</u> , or for which a copy thereof is attached.	
2. From: Yibin Xiang To: Oscient Pharmaceutica	als Corporation
The document was recorded in the United States Patent and Trademark Office at	
Reel <u>018145</u> , Frame <u>0491</u> , or for which a copy thereof is attached.	
3. From: Ravi K. Jalluri To: Oscient Pharmaceutica	als Corporation
The document was recorded in the United States Patent and Trademark Office at	
Reel <u>018145</u> , Frame <u>0491</u> , or for which a copy thereof is attached.	
Additional documents in the chain of title are listed on a supplemental sheet(s).	
As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.	the original owner to the assignee was,
[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO.	be submitted to Assignment Division in See MPEP 302.08]
The undersigned (whose title is supplied below) is authorized to act on behalf of the assigned	э.
/Elizabeth A. Hanley/	June 1, 2010
Signature	Date
Elizabeth A. Hanley	Attorney for Applicants
Printed or Typed Name	Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO:** Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



- 4. From: Anthony C. Arvanites To: Oscient Pharmaceuticals Corporation

  The document was recorded in the United States Patent and Trademark office at

  Reel 018145, Frame 0491, or for which a copy thereof is attached.
- From: Oscient Pharmaceuticals Corporation To: MaxThera, Inc.
   The document was recorded in the United States Patent and Trademark office at Reel 024429,
   Frame 0768, or for which a copy thereof is attached.
- 6. From: MaxThera, Inc.

  To: Biota Scientific Management Pty Ltd

  The document was recorded in the United States Patent and Trademark office at

  Reel 024443, Frame 0128, or for which a copy thereof is attached.